Clover Biopharma jumps on launching COVID vaccine in China's booster dose campaign

Clover Biopharmaceuticals

14/02/2023 06:31

** Shares of Chinese vaccines developer Clover
Biopharmaceuticals Ltd  2197.HK  jump as much as 23.5% to
HK$2.94, their biggest daily pct rise since Nov. 24 if gains
hold
    ** Stock hits the highest since Jan. 17, snapping seven
straight sessions of fall; biggest pct gainer in the Hang Seng
Composite Index  .HSCI  
    ** Sichuan-based co says it has begun the launch of its
COVID-19 vaccine, a recombinant SARS-CoV-2 subunit vaccine, in
China with the first doses delivered and administered in
Changxing in Zhejiang province 
    ** Says it is part of China's national second booster dose
campaign targeting older adults, immunocompromised individuals
and individuals with comorbidities
    ** Co expects to have additional launches in China based on
production capacity and market dynamics, and in Asia Pacific and
Latin America based on the potential to generate significant
near-term revenue
    ** Hong Kong's healthcare index  .HSCIH  eases 1%, while the
Hang Seng Composite Index  .HSCI  and the Hang Seng Index  .HSI 
both slip 0.3%
 (Reporting by Donny Kwok)
 ((donny.kwok@thomsonreuters.com))